ERBB2 and breast cancer: Anti-human epidermal growth factor receptor 2 (HER2) is a monoclonal antibody used in HER2-positive breast cancer, causing cardiotoxicity in nearly 30% of patients, with an even greater risk when used in combination with AC [29,30].